Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).

Se Ik Kim Jeong-Won Lee Kidong Kim Maria Lee Ji Geun Yoo Min Chul Choi Suhyun Hwangbo Young Hwa Kwak Jong Min Lee So-Jin Shin Seung-Hyuk Shim Min Kyu Kim

Published in: Journal of gynecologic oncology (2021)

Compared to BEV, intention-to-treat OLA and actual use of OLA maintenance therapy were significantly associated with decreased disease recurrence risk in patients with BRCA-mutated, PSR HGSOC.

Keyphrases

breast cancer risk
acute lymphoblastic leukemia
acute myeloid leukemia
palliative care
diffuse large b cell lymphoma
multiple myeloma
wild type
hodgkin lymphoma
metastatic colorectal cancer
free survival
endometrial cancer
cell therapy